Actionable news
0
All posts from Actionable news
Actionable news in MDVN: Medivation, Inc.,

Completion of Acquisition or Disposition of Assets

On October6, 2015, Medivation, Inc. (Medivation) completed its acquisition of all rights to talazoparib (MDV3800; formerly referred to as BMN-673) from BioMarin Pharmaceutical Inc. (BioMarin) pursuant to the Asset Purchase Agreement entered into between Medivation and BioMarin dated August21, 2015 (the Agreement). The acquired talazoparib assets include all patents, data, know-how, third party agreements, regulatory materials and inventories. Medivation also assumes certain liabilities related to the acquired assets to the extent they arise after the closing, including liabilities for the ongoing clinical trials of talazoparib, liabilities under certain agreements previously entered into by BioMarin and assigned to Medivation in the transaction, and certain of BioMarins obligations pursuant to its Stock Purchase Agreement with LEAD Therapeutics, Inc., dated February4, 2010, as amended, the agreement under which BioMarin initially acquired BMN-673.

In connection with the closing of the transaction, Medivation has paid BioMarin the upfront payment of $410...


More